Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Abbas Naqvi

Orthopaedic Surgery Oakland Park, FL Medical Doctor

NPI 1861855900 CMS profile 10284198

5597 N Dixie Hwy, Oakland Park, FL 33334

Open in the dashboard

General payments

$15,958

67 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abbas Naqvi of Oakland Park, FL is reported in the CMS Open Payments database as having received $15,958 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,568 31
2024 General $7,461 19
2023 General $322 5
2022 General $521 10
2021 General $86 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abbas Naqvi
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Abbas Naqvi were reported at $7,568. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Abbas Naqvi Orthopaedic Surgery median Middle half National median
2019 $0 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $86 $520 $117–$2,495 $132
2022 $521 $598 $128–$2,731 $149
2023 $322 $461 $128–$2,264 $160
2024 $7,461 $497 $134–$2,475 $164
2025 $7,568 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Smith+Nephew, Inc. $6,121 22 payments
  2. LinkBio Corp $5,416 4 payments
  3. Stryker Corporation $3,504 27 payments
  4. Zimmer Biomet Holdings, Inc. $416 5 payments
  5. Encore Medical, LP $155 1 payment
  6. Ortho Development Corporation $142 1 payment
  7. Heraeus Medical, LLC. $77 1 payment
  8. Supreme Orthopedic Systems, LLC $27 1 payment
  9. Integra LifeSciences Corporation $25 1 payment
  10. MicroPort Orthopedics Inc $23 1 payment
  11. Other $52 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $12,627 21 payments
  2. Food and Beverage $3,331 46 payments
Products named General payments · program years 2021–2025
  1. REAL INTELLIGENCE $3,884 18 payments
  2. MAKO $3,013 20 payments
  3. JOURNEY II Recon Knees $2,960 11 payments
  4. LEGION Revision $1,542 7 payments
  5. JOURNEY $1,471 6 payments
  6. RI Hip Navigation $1,471 6 payments
  7. JOURNEY II Recon Knees $1,018 5 payments
  8. REDAPT $1,018 5 payments
  9. K-15 PORK $752 1 payment
  10. JOURNEY II Recon Knees $524 2 payments
  11. Other $1,936 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

315

Median for Orthopedic Surgery: 203

Drug cost

$3,341

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 39 $2,014
Oxycodone Hcl Generic 60 $438
Methylprednisolone Generic 62 $416
Meloxicam Generic 103 $235
Cefadroxil Generic 36 $199
Tramadol Hcl Generic 15 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$161,005

Of which drugs: $4,157

Medicare patients

343

Average age 74

Services billed

2,619

215 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Ischemic heart disease 27%
Chronic kidney disease 27%
Diabetes 26%
Depression 24%
Osteoporosis 20%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 71 582 $443

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record